Skip to main content
SpringerLink
Log in

Mechanisms and Efficacy of LV Pre-Excitation for Patients with Heart Failure and Supra-Normal Systolic Function

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Ventricular hypertrophy due to genetic mutations of sarcomeric proteins or that associated with long-standing hypertension typically yields a cavity with hyperdynamic ejection, elevated diastolic pressures, and limited filling volumes. The net result is reduced reserve capacity, dyspnea with exertional intolerance, and chest discomfort despite normal appearing coronary vessels. In addition to pharmacologic therapy by agents having negative inotropic effects, recent studies have examined the potential of ventricular pacing using right apical pre-excitation as a treatment for these disorders. This form of pacing can increase end-systolic volume and reduce cavity obliteration in both forms of the disease, yet has no demonstrable acute benefit on diastolic function. Chronic therapy trials have yielded mixed results, with more favorable responses observed in older patients particularly those with hypertensive hypertrophic disease. These data have also highlighted the importance of enhancing systolic reserve rather than diastolic function as a key therapeutic effect from pacing therapy. This review discusses the mechanisms by which pacing with ventricular pre-excitation acutely influences ventricular function, and summarizes results of recent clinical trials, putting the data into perspective regarding the relative role of systolic versus diastolic effects in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH and Goldstein RA. Congestive heart failure with normal systolic function. Am. J. Cardiol. 1984;54:778–782.

    Google Scholar 

  2. Kessler KM. Heart failure with normal systolic function. Update of prevalence, differential diagnosis, prognosis, and therapy. Arch Intern Med 1988;148:2109–2111.

    Google Scholar 

  3. Topol EJ, Traill TA and Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N. Engl. J. Med. 1985;312:277–283.

    Google Scholar 

  4. Vasan RS, Benjamin EJ and Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J. Am. Coll. Cardiol. 1995;26:1565–1574.

    Google Scholar 

  5. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK and Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction:prevalence and mortality in a populationbased cohort. J Am Coll Cardiol 1999;33:1948–1955.

    Google Scholar 

  6. Vasan RS and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria [see comments]. Circulation 2000 101:2118–2121.

    Google Scholar 

  7. Vasan RS and Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch. Intern. Med. 1996;156:1789–1796.

    Google Scholar 

  8. Seidman CE and Seidman JG. Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic Res Cardiol 1998. 93 Suppl 3:13–6:13-16.

    Google Scholar 

  9. Spirito P, Seidman CE, WJ McKenna and BJ Maron. The management of hypertrophic cardiomyopathy. N. Engl. J. Med. 1997;336:775–785.

    Google Scholar 

  10. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE and Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy [see comments]. N. Engl. J. Med. 1992;326:1108–1114.

    Google Scholar 

  11. Soufer R, Wohlgelernter D, Vita NA et al. Intact systolic left ventricular function in clinical congestive heart failure. Am. J. Cardiol. 1985;55:1082–1086.

    Google Scholar 

  12. Faber L, Meissner A, Ziemssen P and Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy:long term follow up of the first series of 25 patients [see comments]. Heart 2000;83:326–331.

    Google Scholar 

  13. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK and Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy:acute results and 3-month follow-up 364 Kass in 25 patients [see comments]. J Am Coll Cardiol 1998;31:252–258.

    Google Scholar 

  14. Robbins RC and Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive ypertrophic cardiomyopathy. J Thorac. Cardiovasc. Surg. 1996;111:586–594.

    Google Scholar 

  15. Pak PH, Maughan WL, Baughman KL, Kieval RS and Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart:Similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 1998;98:242–248.

    Google Scholar 

  16. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG and Tajik AJ. 1997. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial. J. Am. Coll. Cardiol. 29:435–441.

    Google Scholar 

  17. Slade AKB, Sadoul N, Shapiro L, Chojnowska L, Simon J-P, Saumarez RC, Dodinot B, Camm AJ, McKenna WJ and Aliot E. DDD pacing in hypertrophic cardiomyopathy:A multicentre clinical experience. Heart 1996;75:44–49.

    Google Scholar 

  18. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, Chojnowska L, Guize L, Gras D, Jeanrenaud X, Ryden L and PIC Study Group. Pacing in hypertrophic obstructive cardiomyopathy:A randomized crossover study. Eur. Heart J. 1997;18:1249–1256.

    Google Scholar 

  19. Fananapazir L, Cannon ROI, Tripodi D and Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and ?-adrenergic blocker therapy. Circulation 1992;85:2149–2161.

    Google Scholar 

  20. Liu CP, CT Ting, W Lawrence, WL Maughan, MS Chang and DA Kass. Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy:Systolic versus Diastolic Determinants. Circulation 1993;88(Pt. 1):1893–1906.

    Google Scholar 

  21. Nishimura RA, DL Hayes, DM Ilstrup, DR Holmes and AJ Tajik. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1996;27:421–430.

    Google Scholar 

  22. Betocchi S, RO Bonow, SL Bacharach, DR Rosing, BJ Maron and MV Green. Isovolumic relaxation period in hypertrophic cardiomyopathy:Assessment by radionuclide angiography. J. Am. Coll. Cardiol. 1986;7:74–81.

    Google Scholar 

  23. Pavin D, C de Place, H Le Breton, C Leclercq, D Gras, F Victor, P Mabo and JC Daubert. Effects of permanent dual-chamber pacing on mitral regurgitation in hypertrophic obstructive cardiomyopathy [see comments]. Eur. Heart J 1999;20:203–210.

    Google Scholar 

  24. Prinzen FW, WC Hunter, BT Wyman and ER McVeigh. Mapping of regional myocardial strain and work during ventricular pacing:experimental study using magnetic resonance tagging. J Am Coll Cardiol 1999;33:1735–1742.

    Google Scholar 

  25. Wyman BT, WC Hunter, FW Prinzen and ER McVeigh. Mapping propagation of mechanical activation in the paced heart with MRI tagging. Am J Physiol 1999;276:H881–H891

    Google Scholar 

  26. Burkhoff D, RY Oikawa and K. Sagawa. Influence of pacing site on canine left ventricular contraction. Am J Physiol 1986;251:H428–H435

    Google Scholar 

  27. Park RC, WC Little and RA O'Rourke. Effect of alteration of the left ventricular activation sequence on the left ventricular end-systolic pressure-volume relation in closed-chest dogs. Circ. Res. 1985;57:706–717.

    Google Scholar 

  28. Pak PH, WL Maughan, KL Baughman, RS Kieval and DA Kass. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart:Similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 1998;98:242–248.

    Google Scholar 

  29. Suga H. Ventricular Energetics. Physiological Reviews 1990;70:247–277.

    Google Scholar 

  30. Prinzen FW, CH Augustijn, T. Arts, MA Allessie and RS Reneman. Redistribution of myocardial fiber strain and blood flow by asynchronous activation. Am J Physiol 1990;259:H300–H308.

    Google Scholar 

  31. Kass DA, Chen CH, Talbot MW, Rochitte CE, Lima JA, Berger RD and Calkins H. Ventricular pacing with premature excitation for treatment of hypertensivecardiac hypertrophy with cavity-obliteration [see comments]. Circulation 1999;100:807–812.

    Google Scholar 

  32. Fananapazir L, Epstein NE, Curiel RV, Panza JA, Tripodi D and McAreavey D. Long-term result. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731–2742.

    Google Scholar 

  33. Posma JL, Blanksma PK and van der Wall EE. Redistribution of myocardial perfusion during permanent dual chamber pacing in symptomatic non-obstructive hypertrophic cardiomyopathy:A quantitative positron emission tomography study. Heart 1996;75:522–524.

    Google Scholar 

  34. Posma JL, Blanksma PK, van der Wall EE, Vaalburg W, Crijns HJGM and Lie KI. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. Heart 1996;76:358–362.

    Google Scholar 

  35. Heyndrickx GR, Vantrimpont PJ, Rousseau MF and Pouleur H. Effects of asynchrony on myocardial relaxation at rest and during exercise in conscious dogs. Am J Physiol 1988;254:H817–H822.

    Google Scholar 

  36. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME and Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drugrefractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, doubleblind, crossover study (M-PATHY). Circulation 1999;99:2927–2933.

    Google Scholar 

  37. Spirito P and Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999;33:1071–1075.

    Google Scholar 

  38. Levy D, Larson MG, Vasan RS, Kannel WB and Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557–1562.

    Google Scholar 

  39. Kass DA, Chen CH, Talbot MW, Rochitte CE, Lima JA, Berger RD and Calkins H. Ventricular pacing with premature excitation for treatment of hypertensivecardiac hypertrophy with cavity-obliteration [see comments]. Circulation 1999;100:807–812.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine and Biomedical Engineering, Johns Hopkins Medical Institutions, Baltimore, MD, 21287

    David A. Kass (Professor)

Authors
  1. David A. Kass
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kass, D.A. Mechanisms and Efficacy of LV Pre-Excitation for Patients with Heart Failure and Supra-Normal Systolic Function. Heart Fail Rev 5, 357–365 (2000). https://doi.org/10.1023/A:1026515430790

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026515430790

Search

Navigation